Insider · CIK 0001120477
Dinesh Ph D Patel V
Files at PTGX (Protagonist Therapeutics, Inc). First filing Nov 27, 2024, latest Sep 10, 2026.
Dinesh Ph D Patel V files SEC Form 4 as CEO, president and director at PTGX (Protagonist Therapeutics, Inc). Since Nov 27, 2024, Dinesh Ph D Patel V has reported 0 open-market buys worth $0 and 10 open-market sells worth $69M, the latest filed on Sep 10, 2026.
A track record needs three past buys with six months of prices behind them; Dinesh Ph D Patel V has 0, so none is measured yet.
The newest scored trade: sold $18M of PTGX on Sep 8, 2026, filed Sep 10, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 7 sells worth $61M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PTGX: Protagonist Therapeutics, Inc
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Protagonist Therapeutics, Inc | $18M 125,000 shares | -22% | - | |
| 20Weak | Protagonist Therapeutics, Inc | $15M 100,000 shares | -17% | +179% from low0% from high | |
| 28Weak | Protagonist Therapeutics, Inc | $7.5M 75,000 shares | -13% | +128% from low-6% from high | |
| 48Moderate | Protagonist Therapeutics, Inc | $7.5M 75,000 shares | -13% | +128% from low-6% from high | |
| 55Moderate | Protagonist Therapeutics, Inc | $5.5M 54,700 shares | -10% | +146% from low-1% from high | |
| 50Moderate | Protagonist Therapeutics, Inc | $4.1M 48,273 shares | -8% | +137% from low-13% from high | |
| 65Notable | Protagonist Therapeutics, Inc | $2.8M 34,438 shares | -6% | +138% from low-13% from high | |
| 44Moderate | PTGXsell Protagonist Therapeutics, Inc | $571k 10,415 shares | -2% | +57% from low-8% from high | |
| 50Moderate | PTGXsell Protagonist Therapeutics, Inc | $2.9M 52,444 shares | -9% | +57% from low-8% from high | |
| 55Moderate | Protagonist Therapeutics, Inc | $4.7M 100,000 shares | -19% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 10, 2026 | PTGX Protagonist Therapeutics, Inc. | 225,000 0.35% of outstanding | $34M | Aug 10, 2026 | $7.5M |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc. | 75,000 0.12% of outstanding | $7.8M | May 12, 2026 | $5.5M |
| Mar 24, 2026 | PTGX Protagonist Therapeutics, Inc. | 54,700 0.09% of outstanding | $5.4M | Mar 24, 2026 | $4.1M |
| Jan 23, 2026 | PTGX Protagonist Therapeutics, Inc. | 108,273 0.17% of outstanding | $9.2M | Jan 23, 2026 | none |
| Jan 21, 2026 | PTGX Protagonist Therapeutics, Inc | 34,438 0.06% of outstanding | $2.8M | Jan 20, 2026 | none |
| Jul 22, 2025 | PTGX Protagonist Therapeutics, Inc. | 50,000 0.08% of outstanding | $2.8M | Jul 22, 2025 | none |
| Nov 25, 2024 | PTGX Protagonist Therapeutics, Inc. | 100,000 0.17% of outstanding | $4.6M | Nov 25, 2024 | none |
Transactions
The newest 50 of 62 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock10b5-1 | +54,174 | $21.58 | $1.2M | 577,142 | 33 d ago |
| Sep 8, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock10b5-1 | -54,174 | $145.87 | $7.9M | 522,968 | 33 d ago |
| Sep 9, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock10b5-1 | +63,548 | $21.58 | $1.4M | 586,516 | 33 d ago |
| Sep 9, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock10b5-1 | -63,548 | $146.18 | $9.3M | 522,968 | 33 d ago |
| Sep 10, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock10b5-1 | +7,278 | $21.58 | $157k | 530,246 | 33 d ago |
| Sep 10, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock10b5-1 | -7,278 | $144.10 | $1.0M | 522,968 | 33 d ago |
| Sep 8, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative10b5-1 | -54,174 | $0.00 | $0 | 70,826 | 33 d ago |
| Sep 9, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative10b5-1 | -63,548 | $0.00 | $0 | 7,278 | 33 d ago |
| Sep 10, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,278 | $0.00 | $0 | 0 | 33 d ago |
| Sep 3, 2026 | PTGX Protagonist Therapeutics, Inc | GGift Common Stock | -510 | $0.00 | $0 | 522,968 | 35 d ago |
| Aug 10, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock10b5-1 | +65,761 | $21.58 | $1.4M | 589,239 | Aug 12, 2026 |
| Aug 10, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock10b5-1 | -65,761 | $149.11 | $9.8M | 523,478 | Aug 12, 2026 |
| Aug 11, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock10b5-1 | +34,239 | $21.58 | $739k | 557,717 | Aug 12, 2026 |
| Aug 11, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock10b5-1 | -34,239 | $148.52 | $5.1M | 523,478 | Aug 12, 2026 |
| Aug 10, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative10b5-1 | -65,761 | $0.00 | $0 | 159,239 | Aug 12, 2026 |
| Aug 11, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative10b5-1 | -34,239 | $0.00 | $0 | 125,000 | Aug 12, 2026 |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock10b5-1 | +75,000 | $21.58 | $1.6M | 598,478 | May 14, 2026 |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock10b5-1 | -75,000 | $100.12 | $7.5M | 523,478 | May 14, 2026 |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative10b5-1 | -75,000 | $0.00 | $0 | 225,000 | May 14, 2026 |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +75,000 | $21.58 | $1.6M | 598,478 | May 12, 2026 |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -75,000 | $100.12 | $7.5M | 523,478 | May 12, 2026 |
| May 12, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -75,000 | $0.00 | $0 | 225,000 | May 12, 2026 |
| Apr 23, 2026 | PTGX Protagonist Therapeutics, Inc | GGift Common Stock | -1,460 | $0.00 | $0 | 523,478 | Apr 24, 2026 |
| Mar 23, 2026 | PTGX Protagonist Therapeutics, Inc | GGift Common Stock | -50,000 | $0.00 | $0 | 524,938 | Mar 25, 2026 |
| Mar 24, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +59 | $8.58 | $506 | 524,997 | Mar 25, 2026 |
| Mar 24, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -59 | $101.00 | $5,959 | 524,938 | Mar 25, 2026 |
| Mar 25, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +54,641 | $8.58 | $469k | 579,579 | Mar 25, 2026 |
| Mar 25, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -54,641 | $101.00 | $5.5M | 524,938 | Mar 25, 2026 |
| Mar 24, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -59 | $0.00 | $0 | 54,641 | Mar 25, 2026 |
| Mar 25, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -54,641 | $0.00 | $0 | 0 | Mar 25, 2026 |
| Jan 23, 2026 | PTGX Protagonist Therapeutics, Inc | GGift Common Stock | -6,000 | $0.00 | $0 | 574,505 | Jan 27, 2026 |
| Jan 23, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +19,315 | $4.21 | $81k | 593,820 | Jan 27, 2026 |
| Jan 23, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -19,315 | $84.59 | $1.6M | 574,505 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +10,685 | $4.21 | $45k | 585,190 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -10,685 | $84.00 | $898k | 574,505 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +14,205 | $21.58 | $307k | 588,710 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -14,205 | $84.05 | $1.2M | 574,505 | Jan 27, 2026 |
| Jan 27, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +4,068 | $21.58 | $88k | 578,573 | Jan 27, 2026 |
| Jan 27, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -4,068 | $83.19 | $338k | 574,505 | Jan 27, 2026 |
| Jan 23, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -19,315 | $0.00 | $0 | 10,685 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -10,685 | $0.00 | $0 | 0 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -14,205 | $0.00 | $0 | 304,068 | Jan 27, 2026 |
| Jan 27, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -4,068 | $0.00 | $0 | 300,000 | Jan 27, 2026 |
| Jan 20, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -34,438 | $82.48 | $2.8M | 580,505 | Jan 21, 2026 |
| Jan 2, 2026 | PTGX Protagonist Therapeutics, Inc | AGrant or award Common Stock | +95,400 | $0.00 | $0 | 614,943 | Jan 6, 2026 |
| Jan 2, 2026 | PTGX Protagonist Therapeutics, Inc | AGrant or award Stock Option (right to buy)derivative | +120,200 | $0.00 | $0 | 120,200 | Jan 6, 2026 |
| Nov 21, 2025 | PTGX Protagonist Therapeutics, Inc | GGift Common Stock | -440 | $0.00 | $0 | 519,543 | Nov 24, 2025 |
| Sep 16, 2025 | PTGX Protagonist Therapeutics, Inc | GGift Common Stock | -620 | $0.00 | $0 | 519,983 | Sep 18, 2025 |
| Jul 25, 2025 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -10,415 | $54.78 | $571k | 520,603 | Jul 28, 2025 |
| Jul 21, 2025 | PTGX Protagonist Therapeutics, Inc | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 583,462 | Jul 23, 2025 |
Questions about Dinesh Ph D Patel V
Answered from the filings on this page, as of the latest one.
Is Dinesh Ph D Patel V buying or selling?
In the last 12 months Dinesh Ph D Patel V reported 0 open-market buys worth $0 and 7 open-market sells worth $61M on SEC Form 4; the latest was sold $18M of PTGX on Sep 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Dinesh Ph D Patel V's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dinesh Ph D Patel V has 0.
Where does Dinesh Ph D Patel V file Form 4?
Dinesh Ph D Patel V has filed Form 4 at PTGX (Protagonist Therapeutics, Inc) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.